Bimokalner
CAS 2243284-19-5
MF C15H18F5NOS MW 355.4 g/mol
- KEY5KKX6QY
- orb2663976
- (1S,2S,4R)-N-[[3-(pentafluoro-λ6-sulfanyl)phenyl]methyl]bicyclo[2.2.1]heptane-2-carboxamide
(1S,2S,4R)-N-{[3-(pentafluoro-λ6sulfanyl)phenyl]methyl} bicyclo[2.2.1]heptane-2-carboxamide
voltage-gated potassium channel (Kv7.4) agonist
Bimokalner is an investigational new drug under evaluation for preventing and treating hearing loss caused by cisplatin treatment. It is a voltage-gated potassium channel agonist targeting Kv7.4 and is being developed by Acousia Therapeutics GmbH.[1][2]
PAT
Compounds useful as potassium channel openers, Publication Number: US-11884642-B2, Priority Date: 2017-02-28, Grant Date: 2024-01-30
- Novel Compounds Useful As Potassium Channel OpenersPublication Number: KR-20210134826-APriority Date: 2017-02-28
- Novel compounds useful as potassium channel openersPublication Number: KR-102382795-B1Priority Date: 2017-02-28Grant Date: 2022-04-05
- Novel Compounds Useful As Potassium Channel OpenersPublication Number: KR-102443685-B1Priority Date: 2017-02-28Grant Date: 2022-09-15
- Compounds useful as potassium channel openersPublication Number: CN-114105942-BPriority Date: 2017-02-28Grant Date: 2024-07-12
- Novel compounds useful as potassium channel openers.Publication Number: JP-7474289-B2Priority Date: 2017-02-28Grant Date: 2024-04-24
- Compounds useful as potassium channel openersPublication Number: US-11034665-B2Priority Date: 2017-02-28Grant Date: 2021-06-15
- Novel compounds useful as potassium channel openersPublication Number: US-2021261518-A1Priority Date: 2017-02-28
- Novel compounds useful as potassium channel openersPublication Number: AU-2018227005-B2Priority Date: 2017-02-28Grant Date: 2021-11-11
- Compounds useful as potassium channel openersPublication Number: CN-110312710-BPriority Date: 2017-02-28Grant Date: 2022-02-15
- New compounds useful as potassium channel openersPublication Number: CN-114105942-APriority Date: 2017-02-28
- Pentacyclothienyl and indanyl urea derivatives as potassium channel openersPublication Number: EP-3567034-A1Priority Date: 2017-02-28
- New Compounds Useful as Potassium Channel OpenersPublication Number: KR-20190105058-APriority Date: 2017-02-28
- Novel compounds useful as potassium channel openersPublication Number: US-2020157072-A1Priority Date: 2017-02-28
- Novel compounds useful as potassium channel openersPublication Number: WO-2018158256-A2Priority Date: 2017-02-28
- Pentacyclothienyl and indanyl urea derivatives as potassium channel openersPublication Number: EP-3567034-B1Priority Date: 2017-02-28Grant Date: 2020-10-28
PAT
(1R,2R,4S)-rel-N-(3-(pentafluorosulfanyl)benzyl)bicyclo[2.2.1]heptane-2-carboxamide
AS ON JUNE2025 4.45 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
……
References
- “Bimokalner”. PatSnap.
- Tavanai E, Rahimi V, Khalili ME, Falahzadeh S, Motasaddi Zarandy M, Mohammadkhani G (2024). “Age-related hearing loss: An updated and comprehensive review of the interventions”. Iranian Journal of Basic Medical Sciences. 27 (3): 256–269. doi:10.22038/IJBMS.2023.72863.15849. PMC 10849199. PMID 38333758.
| Clinical data | |
|---|---|
| Other names | ACOU085 |
| Identifiers | |
| IUPAC name | |
| CAS Number | 2243284-19-5 |
| PubChem CID | 135309173 |
| UNII | KEY5KKX6QY |
| Chemical and physical data | |
| Formula | C15H18F5NOS |
| Molar mass | 355.37 g·mol−1 |
| 3D model (JSmol) | Interactive image |
| SMILES | |
| InChI | |
///////////Bimokalner, Acousia Therapeutics, KEY5KKX6QY, orb 2663976